Celgene has formed a collaboration with Quanticel and its capital investor Versant Ventures that provides the start-up with an initial investment of US$45 M over 3.5 years to support the discovery of novel targeted cancer drugs using its proprietary genomic analysis technology. The innovatively structured deal gives Celgene an undisclosed equity stake in Quanticel as well as an exclusive option to acquire the company at a later date and highlights a trend of early-stage partnering in oncology.